Antifungal activity of *Arctotis arctotoides* (L.f.) O. Hoffm. and *Gasteria bicolor* Haw. against opportunistic fungi associated with human immunodeficiency virus/acquired immunodeficiency syndrome

Wilfred M. Otang, Donald S. Grierson, Roland N. Ndip

Department of Botany, University of Fort Hare, Alice, South Africa, 1Department of Biochemistry and Microbiology, University of Fort Hare, Alice, South Africa, 2Department of Microbiology and Parasitology, University of Buea, Buea, Cameroon

Submitted: 11-08-2011 Revised: 19-09-2011 Published: 23-05-2012

**ABSTRACT**

**Background:** In South Africa where many patients are immunocompromised as a result of the AIDS pandemic, opportunistic fungal infections such as candidiasis caused mainly by *Candida albicans* are common. *Arctotis arctotoides* and *Gasteria bicolor* are two plants which are frequently and commonly used in traditional medicine in the treatment of HIV patients. **Aim:** The aim of this study was to investigate the antifungal activity of *A. arctotoides* and *G. bicolor* against opportunistic fungi common in HIV/AIDS patients. **Materials and Methods:** The agar diffusion and micro-dilution methods were used to determine the antifungal activities of the medicinal plant extracts against 10 opportunistic fungi. **Results:** All the hexane and acetone extracts were active against at least one of the fungi with zones of inhibition varying from 8 to 32 mm, while none of the aqueous extracts was active against any of the fungi. The inhibitory activity of the active extracts, based on the overall mean inhibition diameters, was in the order: *A. arctotoides* (hexane) > *A. arctotoides* (acetone) > *G. bicolor* (hexane) > *G. bicolor* (acetone). The most susceptible fungi, based on the overall mean diameter of growth inhibition, were *Candida glabrata*, *C. krusei*, and *Microsporum canis*, while *Cryptococcus neoformans*, *Trypophyton tonsurans*, and *Microsporum gypseum* were not susceptible to any of the extracts even at 5 mg/ml which was the highest concentration used. **Conclusion:** This study validates the use of these plants in traditional medicine in the treatment of secondary fungal infections in HIV/AIDS patients.

**Key words:** Antifungal activity, arctotis arctotoides, gasteria bicolor, human immunodeficiency virus/acquired immunodeficiency syndrome, opportunistic fungi

**INTRODUCTION**

In many patients who are immunocompromised as a result of the acquired immunodeficiency syndrome (AIDS) pandemic, opportunistic fungal infections are common. Some of these pathogens are: *Candida albicans* which is an opportunistic fungus that can cause local and systemic infections in predisposed persons, commonly affecting immunologically compromised patients and those undergoing prolonged antibiotic treatment. In human immunodeficiency virus (HIV) patients, the presence of oral candidiasis is the earliest opportunistic infection, and is displayed by two-thirds of HIV-infected individuals. *Cryptococcus neoformans* is one of the most important opportunistic fungal pathogens that causes life-threatening meningitis of the central nervous system in both immunocompromised and apparently immunocompetent patients. *Aspergillus fumigatus* may be associated with respiratory infections; among the pathogenic fungi, the dermatophytes have the ability to invade keratinised tissues of animals and humans and cause dermatophytosis which is the most common human contagious fungal disease. *Microsporum gypseum* and *Trichophyton mentagrophytes* are dermatomycetes of which the former causes infections often referred to as ringworm.

With the increasing incidence of strains of fungi with
multiple antibiotic resistance and the persistence of fungal infections in immunocompromised individuals, it is of great importance to find effective treatments against fungal infections and other microbial pathogens. On the basis of the knowledge that plants have their own defense against fungal pathogens and are traditionally used for the treatment of human mycoses, they appear as an interesting source for the discovery of new antifungal drugs. Hence, much attention has been drawn to plant-derived fungicides in recent years.

In South Africa, 60–80% of the population relies solely or partially on traditional herbal medicines to treat a variety of animal and human diseases. Many traditionally used medicinal plants are therefore sold in the market places due to increased demands for cheap medicines, high unemployment rate, and increase in HIV infections. This high dependence on plants for medicinal purposes necessitates the need for the scientific validation of their therapeutic value and safety.

Arctotis arctotoides (Asteraceae) is a decumbent herb commonly found as a roadside weed in most coastal districts of South Africa. The Xhosa-speaking people in the Eastern Cape Province apply the juice from the leaf as a topical paste to treat wounds. The inhibitory activity of the aqueous extracts of the leaves of A. arctotoides against six fungal species, with growth inhibitions ranging from 56.23% on Aspergillus tamarii to 95.2% on Penicillium digitatum at 0.1 mg/ml, has also been reported. The acetone and methanol extracts of the root of this plant demonstrated significant activity against five fungal species: Aspergillus flavus, A. niger, Fusarium oxysporum, Mucor beamalis, and Penicillium notatum. Inhibition of fungal growth ranged from 56.23% on A. flavus to 100% on P. notatum and M. beamalis at 5.0 mg/ml. The antibacterial activities of A. arctotoides have previously been reported in the literature. The succulent genus, Gasteria, which comprises 16 species, is endemic to South Africa and has its main centers of distribution in the savanna region in the Eastern Cape. Previously, this genus was classified in the large heterogeneous Liliaceae family but is now classified under the family Asphodelaceae. The selection of the medicinal plants used in this study was mainly based on their ethnomedical evidence of use for the management of opportunistic fungal infections in HIV/AIDS patients. On the basis of our previous ethnobotanical survey both A. arctotoides and G. bicolor were commonly cited by HIV/AIDS patients and traditional healers for their usage in the management of symptoms of opportunistic fungal infections. The most frequently cited were symptoms of oral candidiasis; oral thrush, oral mucosal lesions, symptoms of oesopharyngeal candidiasis; pain and difficulty in swallowing, altered taste, and symptoms of dermatomycosis; ring-like patch on the skin, skin itch, and skin rash. However, the antifungal activity of these plants against opportunistic fungi in HIV/AIDS has not been investigated. In this study, the hexane, acetone, and aqueous extracts of G. bicolor and A. arctotoides were analysed for their in vitro antifungal activity against a panel of standardized opportunistic pathogenic fungi including dermatomycetes found in HIV-infected patients.

MATERIALS AND METHODS

Plant material

A. arctotoides was collected at the Agricultural Research Farm of the University of Fort Hare, South Africa, while G. bicolor was supplied by an herbalist. The plants were authenticated at the Griffin Herbarium of the Department of Botany, University of Fort Hare, where voucher specimens were deposited (A. Arctotoides: W28, G. bicolor: W31).

Extraction procedure

Leaf samples of G. bicolor and A. arctotoides were chopped, dried in an oven at 40 °C and ground into fine powder. The ground samples were put into separate conical flasks containing acetone, hexane, and water and shaken for 24 h on an orbital shaker. After filtering with a Buchner funnel and Whatman No. 1 filter paper, the hexane and acetone filtrates were concentrated to dryness under reduced pressure at a maximum of 40 °C using a rotavapor. Aqueous filtrates were freeze-dried. Each extract was resuspended in the respective solvent of extraction to yield a 20 mg/ml stock solution.

Microorganisms and media

The fungi used in this study were chosen primarily on the basis of their importance as opportunistic pathogens of humans infected with HIV/AIDS. Strains from the American Type Culture Collection (ATCC) were used: C. albicans ATCC 2091, C. krusei ATCC 14243, C. glabrata ATCC 2001, C. neoformans ATCC 66031, A. fumigatus ATCC 204305, A. niger ATCC 16888, Trichophyton tonsurans ATCC 28942, T. mentagrophytes ATCC 201382, M. gypseum ATCC 24102, and M. canis ATCC 36299. Both Sabouraud dextrose agar (SDA) and Sabouraud dextrose broth (SDB) were prepared according to the manufacturer’s instructions. The fungi were maintained at 4 °C on SDA plates, and the inoculum for the assays was prepared by diluting scraped cell mass in 0.85% NaCl solution, adjusted to 0.5 McFarland standard and confirmed by spectrophotometric reading at 580 nm. Cell suspensions were finally diluted to 10^6 CFU mL⁻¹ for the use in the assays.

Antifungal susceptibility assays

The agar diffusion and microdilution methods were used...
to determine the antifungal activities of the medicinal plant extracts against the opportunistic fungi.\(^\text{[1]}\)

**Agar well diffusion assay**
The agar diffusion assay was carried out with slight modifications.\(^\text{[10]}\) Using the micropipette, 100 µl of 0.5 McFarland solution of *C. albicans* culture in 0.85% sterile distilled water (SDW) was placed over the surface of an agar plate, and spread using a sterile inoculation loop. The same procedure was followed for the other fungi. Using a sterile cork borer, four holes (5 mm in diameter) were punched in each of the culture plates. In the first hole, 50 µl of a positive control drug was added (Amphotericin B for *C. neoformans* and *Aspergillus* spp., Nystatin for *Candida* spp., and Griesefulvin for the dermatomycetes); 50 µl of the corresponding extract solvent was added as a negative control in the second hole; and 50 µl of the plant extract was added in the third and last holes at concentrations of 25 and 50 mg/ml, respectively. Each test was duplicated. The culture plates were then incubated at 37 °C, and the results were observed after 24 h to 6 days depending on the fungi. The clear zone around each well was measured in mm, indicating the activity of the plant extract against the fungal organisms.

**Microdilution assay**
The microdilution method was employed to determine the minimum inhibitory concentration (MIC) of the plant extracts using 96 well microtitre plates.\(^\text{[16]}\) Initially, 120 µl of SDW was added into each well of the first (A) and last (H) rows and also into all the wells of the last column.\(^\text{[12]}\) Then, 120 µl of SDB was added into each well of the second row (B) and 150 µl of SDB was added into the remaining wells of the first column and 100 µl into the rest of the wells from the second column rightward. Fifty microliters of the plant extract were then added into the third well of the first column while 50 µl of the positive and negative control were separately added into the remaining wells of the first column. A two-fold serial dilution was done by mixing the contents in each well of the first column (starting from the third row) and transferring 100 µl into the second well of the same row and the procedure was repeated up to the 11th well of the same row and the last 100 µl from the 11th well was discarded. Hence various concentrations of the plant extracts ranging from 5 mg/ml to 0.005 mg/ml were prepared in the wells, following the two-fold dilution method. Thereafter, 20 µl of 0.5 McFarland fungal suspension was inoculated into the wells except those which contained SDW. The growth of the fungi was measured by determining the absorbance at 620 nm with a microtitre plate reader before and after incubation. The plates were incubated at 37°C at various durations depending on the fungi (24 h for yeasts, 48 h for *Aspergillus* species, and 6 days for the dermatomycetes). The lowest concentration which inhibited the growth of the fungi was considered as the MIC of the extract.

**Determination of the minimum fungicidal concentration**
The MFC was determined by inoculating the contents from the MIC plates onto SDA plates, and the results were observed after incubation at 37°C at various durations depending on the fungi. The presence of the fungal colonies on the agar plates was an indication that the plant extract only inhibited the growth of the fungi without killing them and the absence indicated that the plant extract was able to kill the fungal organisms.\(^\text{[9]}\) The smallest concentration of the plant extract that was able to kill the microorganisms was considered as the minimum fungicidal concentration (MFC).

**RESULTS**

Among the six plant extracts that were tested against the 10 opportunistic fungi, all the hexane and acetone extracts were active against at least one of the fungi with zones of inhibition varying from 8 to 32 mm [Table 1]. None of the aqueous extracts was active against any of the fungi. For *A. arctotoides*, the hexane extract was active against 6 out of the 10 fungi, while the acetone extract was active against 7 out of the 10 tested fungi. The hexane and acetone extracts of *G. bicolor* were active against six and five of the 10 tested fungi, respectively. The inhibitory activity of the active extracts based on the overall mean inhibition diameters was in the order: *A. arctotoides* (hexane) > *A. arctotoides* (acetone) > *G. bicolor* (hexane) > *G. bicolor* (acetone) [Figure 1]. The highest activity against the tested fungi was obtained with the hexane extract of *A. arctotoides* with inhibition zones diameters of 32, 25, and 22 mm against *C. glabrata*, *T. mucoides*, and *M. canis*, respectively [Table 1]. The lowest activity was obtained with the hexane extract of *G. bicolor* with inhibition zones diameter of 8 mm against *A. fumigatus*.

The most susceptible fungi based on the overall mean diameter of growth inhibition were *C. glabrata*, *C. krusei*, and *M. canis*, while *C. neoformans*, *T. tonsurans*, and *M. gypseum* were not susceptible to any of the extracts even at 5 mg/ml which was the highest concentration used [Figure 2]. *T. mucoides* was susceptible to *A. arctotoides*, but not to *G. bicolor* extracts.

The varying concentrations between 5 and 0.005 mg/ml of the plant extracts were tested in order to determine their MICs. The MICs and MFCs of the plant extracts against the 10 tested fungi are presented in Table 2. For *A. arctotoides*, the lowest MICs were obtained with the hexane extract (0.005 mg/ml against *T. mucoides* and 0.04 mg/ml against *A. niger*) and the acetone extract (0.04 mg/ml against...
DISCUSSION

Both *A. arctotoides* and *G. bicolor* were chosen for this study because they are widely used in traditional medicine and are readily available in the Eastern Cape Province of South Africa. Since the hexane and acetone extracts of both plants were active against at least one of the yeasts (especially *Candida* spp.) and moulds (including the dermatomycetes *A. fumigatus* and *A. niger*), the lowest MICs were obtained with the hexane extract: 0.04 mg/ml against *A. fumigatus* and 1.25 mg/ml against *C. glabrata*. The acetone extract of *G. bicolor* was inactive against *A. niger* and *A. fumigatus* at the concentrations tested.

| Plant       | Solvent | Concentration (mg/ml) | Inhibition zone diameter (mm) |
|-------------|---------|-----------------------|-------------------------------|
| **A. arctotoides** | Hexane 25 | 15 ± 0.2<sup>a</sup> | **Ca** 16 ± 0.5<sup>a</sup> |
|             |         50 | 16 ± 1.4<sup>a</sup>  |                               |
| Acetone     | 25      | 13 ± 0.9<sup>b</sup>  |                               |
|             | 50      | 14 ± 1.7<sup>b</sup>  |                               |
| **G. bicolor** | Hexane 25 | 14 ± 2.1<sup>a</sup> | **Ck** 19 ± 0.2<sup>a</sup> |
|             | 50      | 14 ± 2.0<sup>b</sup>  |                               |
| Acetone     | 25      | 10 ± 2.3<sup>c</sup>  |                               |
|             | 50      | 13 ± 2.1<sup>c</sup>  |                               |
| **Control** |         50 | 19 ± 0.2<sup>a</sup> | **Ck** 18 ± 0.2<sup>a</sup> |

Values are means of inhibition zone diameter ± standard deviations of three replicates.

*Values within a column followed by the same superscript are not significantly different (P > 0.05).* Ca = *C. albicans*, Ck = *C. krusei*, Cg = *C. glabrata*, Cn = *Cryptococcus neoformans*, Af = *A. fumigatus*, An = *A. niger*, Tt = *T. tonsurans*, Tm = *T. mucoides*, Mg = *M. gypseum*, Mc = *M. canis*.
M. canis and T. mucoides) and considering that the mean inhibition zone diameters of A. arctotoides (hexane) and the positive controls were not significantly different (P > 0.05) [Figure 2], this suggest that both A. arctotoides and G. bicolor appear to have high efficacy with a broad spectrum of antifungal activity. The overall antifungal activity evaluated by the diameter of the inhibition zone of fungal growth indicates that among the four active extracts, the hexane extract of A. arctotoides exhibited the highest antifungal activity, comparable to that of the reference drug (Amphotericin B). This highlights the medicinal value of A. arctotoides as a potential source for drug development amidst the obvious dearth of effective and safe antifungal drugs. On the other hand, the absence of any significant inhibition with any of the remaining three extracts when compared to the control agent was attributed the fact that crude plant extracts are generally mixtures of active and nonactive compounds.

For a crude extract to be considered active, it should have a MIC value of 0.1 mg/ml or less.[17] Considering the above criterion, both A. arctotoides and G. bicolor are worthy of further investigation. Hence, these extracts are being subjected to bioassay-guided fractionations in order to isolate the compound/s responsible for the activity. Previous reports have shown that the aqueous extract of A. arctotoides was inhibitory (though not fungicidal) against Aspergillus tamarii and Penicillium digitatum.[10] However, this study has shown that the extracts of A. arctotoides were fungicidal against some of the opportunistic fungi common in HIV infections. This discrepancy could be attributed to the fact that the concentration of active compounds in a plant may vary depending on the time of collection.[18]

Scientific studies on the antifungal activity of A. arctotoides and G. bicolor on opportunistic fungi in HIV/AIDS patients are scarce. Candidiasis is the most common opportunistic fungal infection found in HIV/AIDS patients.[19] Oral candidiasis is common in the elderly, HIV-infected patients, and also in patients with the long-term use of broad-spectrum antibiotics, corticosteroids, and immunosuppressants.[19] The results of this in vitro study showing the fungicidal effect of the hexane and acetone extracts of A. arctotoides and G. bicolor against Candida spp. suggests that these plants possess a strong potential therapeutic value against candidiasis. Therefore, the extracts with strong fungicidal activity against these opportunistic fungi might produce encouraging clinical outcomes. Notwithstanding, future research is warranted to identify the active compounds that inhibit candida growth as well as the appropriate dosages and formulations for the clinical use.

Human infections, particularly those involving the skin
and mucosal surfaces, constitute a serious problem, especially in tropical and subtropical developing countries, dermatomycetes and *Candida* spp. being the most frequent pathogens.[5] Hence, the fact that the hexane and acetone extracts of the test plants were fungicidal and inhibitory against *T. mucoides* and *M. canis*, respectively, further justifies the ethnopharmacological use of these species against mycotic infections and also highlights the possibility of using them as sources of antifungal compounds against fungi in dermatomycoses.

The results of this study have shown that the hexane and acetone extracts obtained from both *G. bicolor* and *A. arctotoides* were active against at least one of the opportunistic fungi. This highlights the potential of both *G. bicolor* and *A. arctotoides* as antifungal agents, and this increases the likelihood for the discovery of new phytomedicines and active principles employed in the treatment of mycoses associated with HIV/AIDS. Generally, the hexane extract of both plants exhibited a stronger fungicidal activity than the acetone extracts, while the aqueous extracts were inactive. Although this study validates the use of these plants in traditional medicine in the treatment of secondary fungal infections in HIV/AIDS patients, further research is warranted in the isolation and identification of the active principles.

**ACKNOWLEDGMENTS**

We greatly appreciate the Govan Mbeki Research and Development Centre (GMRDC) of the University of Fort Hare and the National Research Foundation (NRF), South Africa, for financing this project.

**REFERENCES**

1. Shai LJ, McGaw LJ, Masoko P, Eloff JN. Antifungal and antibacterial activity of seven traditionally used South African plant species active against *Candida albicans*. S Afr J Bot 2008;74:677-84.

2. Duarte MC, Figueira GM, Sartoratto A, Rehder LG, Delarmelina C. Anti-*Candida* activity of Brazilian medicinal plants. J Ethnopharmacol 2005;97:305-11.

3. Hamza OJ, van den Beukel CJ, Matee MI, Moshi MJ, Mkx FH, Selemane HO, *et al*. Antifungal activity of some Tanzanian plants used traditionally for the treatment of fungal infections. J Ethnopharmacol 2006;108:124-32.

4. Cruz MC, Santos PO, Barbosa AM Jr, de Melo DL, Alviano CS, Antonioli AR, *et al*. Antifungal activity of Brazilian medicinal plants involved in popular treatment of mycoses. J Ethnopharmacol 2007;111:409-12.

5. Gurgel LA, Sidrim JJ, Martins DT, Cechinel Filho V, Rao VS. *In vitro* antifungal activity of dragon’s blood from Croton urucurana against dermatophytes. J Ethnopharmacol 2005;97:409-12.

6. Jones NP, Arnason JT, Abou-Zaied M, Akpagana K, Sanchez-Vindas P, Smith ML. Antifungal activity of extracts from medicinal plants used by First Nations Peoples of Eastern Canada. J Ethnopharmacol 2000;73:191-8.

7. Kelly SL, Lamb DC, Kelly DE, Manning NJ, Loeffler J, Hebart H, *et al*. Resistance to fluconazole and cross-resistance to amphotericin B in *Candida albicans* from AIDS patients caused by defective sterol D3,5-desaturation. FEBS Lett 1997;400:80-2.

8. Stein AC, Alvarez SS, Avancini C, Zacchino S, von Poser G. Antifungal activity of some coumarins obtained from species of *Pterocaulon* (Asteraceae). J Ethnopharmacol 2006;107:95-8.

9. Afamolaj AJ, Jimoh FO, Sofidaya MO, Koduru S, Lewu FB. Medicinal Potential of the root of *Arctotis arctotoides*. Pharm Biol 2007;45:486-93.

10. Afamolaj AJ. Extracts from the shoots of *Arctotis arctotoides* inhibit the growth of bacteria and fungi. Pharm Biol 2003;41:22-5.

11. Sultana N, Afamolaj AJ, Bhuiyan RF. Anticorimbic compounds from the shoots of *Arctotis arctotoides*. Bangladesh J Sci Ind Res 2008;43:89-96.

12. Dagne E, Van Wyk BE, Mueller M, Steglich W. Three dihydroantroecanes from *Gasteria bicolor*. Phytochemistry 1996;41:795-9.

13. Sultana N, Afamolaj AJ. Bioactive sesquiterpene lactones isolated from the shoots of *Arctotis arctotoides*. S Afr J Bot 2003;69:1-3.

14. Otang WM, Grierson DS, Ndip RN. Ethnobotanical survey of medicinal plants used in the management of opportunistic fungal infections in HIV/AIDS patients in the Amathole District of the Eastern Cape Province, South Africa. J Med Pl Res 2012;6:2071-80.

15. Koduru S, Grierson DS, Afamolaj AJ. Antimicrobial Activity of *Solanium aculeastrum*. Pharm Biol 2006;44:283-6.

16. Samie, Tambani T, Harshfield E, Green E, Ramalivhana JE, Bessong PO. Antifungal activities of selected Venda medicinal plants against *Candida albicans*, *Candida krusei* and *Cryptococcus neoformans* isolated from South African AIDS patients. Afr J Biotechnol 2010;9:2965-6.

17. Aigliannis N, Kalpotzakis E, Mitaku S, Chinou IB. Composition and antimicrobial activity of the essential oils of two *Origanum* species. J Agric Food Chem 2001;49:4168-70.

18. Jainkittivong A, Butsarakamruha T, Langlais RP. Antifungal activity of *Arctotis arctotoides*. J Ethnopharmacol 2006;107:95-8.

Cite this article as: Otang WM, Grierson DS, Ndip RN. Antifungal activity of *Arctotis arctotoides* (L.f.) O. Hoffm. and *Gasteria bicolor* Haw. against opportunistic fungi associated with human immunodeficiency virus/acquired immunodeficiency syndrome. Phcog Mag 2012;8:135-40.

Source of Support: Govan Mbeki Research and Development Centre (GMRDC) of the University of Fort Hare and the National Research Foundation (NRF), South Africa, Conflict of Interest: None declared.